Keyword: Turku Bioscience Centre

This page displays contents related to the keyword.

BioCity Student Symposium – Students are the Solution, 24 August 2022

13.05.2022

This year BioCity Student Symposium titled Students are the Solution is arranged on-site by PhD researchers from The University of Turku and Abo Akademi University together with BioCity Turku and InFLAMES Flagship in Cave theatre - Visitor and Innovation Centre Joki, 24th August 2022.

31st BioCity Symposium 25-26 August 2022

01.04.2022

This year BioCity Symposium is arranged on-site in Mauno Conference Centre, BioCity, together with InFLAMES Research Flagship 25–26 August 2022, with the title Solution is in Immunity. Registration is now open until 11 August 2022.

Call for BioCity Turku new research programs – Deadline 15 April

21.03.2022

BioCity Turku is an umbrella organization supporting and coordinating research on life sciences and molecular medicine in University of Turku and Åbo Akademi University. BioCity Turku research programs strengthen the multidisciplinary and interdisciplinary research collaboration within the Turku campus. BioCity Turku asks for proposals for new research programs for 2022-2026.

BioCity Symposium Celebrates its 30th Anniversary in August 2021

11.05.2021

The annual BioCity Symposium is in August 19th–20th with the title Cancer – Breaking Bad. This series of meetings organized since 1991 has become the most important annual get-together in the fields of biosciences and molecular medicine in Turku. The symposium gathers together hundreds of participants each year and offers talks from cutting-edge international researchers.

Novel Therapy-resistance Mechanism Promoting the Growth of Breast Cancer Brain Metastasis

29.01.2021

SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitised anti-HER2 resistant breast cancer brain metastasis to targeted therapy.

Researchers Develop a Simplified Method to Modify Disease Signaling with Light

22.10.2020

Cellular optogenetics is a technique that allows researchers to use light to precisely control cell signaling and function in space and time enabling the investigation of mechanisms involved in disease processes. A research team at the Turku Bioscience Centre of the University of Turku have developed a novel way to make cellular optogenetic tools much easier to monitor and apply, and showed how they can be used to investigate the cellular side effects of medicines used to treat cancer.